IVVD trades 1039.1% below Wall Street's consensus target of $9.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IVVD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 6, 2026, Invivyd, Inc. (IVVD) has a Wall Street consensus price target of $9.50, based on estimates from 7 covering analysts. With the stock currently trading at $0.83, this represents a potential upside of +1039.1%. The company has a market capitalization of $111M.
Analyst price targets range from a low of $9.00 to a high of $10.00, representing a 11% spread in expectations. The median target of $9.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, IVVD trades at a trailing P/E of -2.8x. Analysts expect EPS to grow -67.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
REGNRegeneron Pharmaceuticals, Inc. | $67.5B | $649.81 | $836.00 | +28.7% | Buy | 14.0x | 48 |
VRTXVertex Pharmaceuticals Incorporated | $134.7B | $529.59 | $556.00 | +5.0% | Buy | 27.4x | 56 |
MNKDMannKind Corporation | $1.3B | $4.27 | $8.50 | +99.1% | Buy | — | 19 |
ADMAADMA Biologics, Inc. | $2.1B | $9.16 | $21.00 | +129.3% | Buy | 11.1x | 10 |
SABSSAB Biotherapeutics, Inc. | $210M | $3.92 | $10.25 | +161.5% | Buy | — | 8 |
ABBVAbbVie Inc. | $450.1B | $254.76 | $258.00 | +1.3% | Buy | 17.9x | 41 |
LLYEli Lilly and Company | $1.1T | $1200.06 | $1269.94 | +5.8% | Buy | 32.8x | 45 |
ALNYAlnylam Pharmaceuticals, Inc. | $41.8B | $313.04 | $450.64 | +44.0% | Buy | 42.1x | 52 |
RCKTRocket Pharmaceuticals, Inc. | $436M | $3.99 | $5.00 | +25.3% | Buy | — | 19 |
IMVTImmunovant, Inc. | $7.9B | $38.60 | $45.00 | +16.6% | Buy | — | 23 |
Quick answers to the most common questions about buying IVVD stock.
The consensus Wall Street price target for IVVD is $9.5, representing 1039.1% upside from the current price of $0.834. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IVVD has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $9.5 implies 1039.1% upside from current levels.
IVVD's current price is $0.834 with a consensus target of $9.5 (1039.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for IVVD, while the most conservative target is $9. The consensus of $9.5 represents the median expectation. These targets typically reflect 12-month expectations.
IVVD is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IVVD stock forecast based on 7 Wall Street analysts shows a consensus price target of $9.5, with estimates ranging from $9 (bear case) to $10 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on IVVD, with a "Buy" consensus rating and $9.5 price target (1039.1% upside). 4 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IVVD analyst price targets range from $9 to $10, a 11% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $9.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.